# Narratives: claude-sonnet-4-6

## Run 1 (77.5s)

# Toxicogenomics Dose-Response Interpretation Report

## Executive Summary

Analysis of 32 dose-responsive genes (BMD range 0.2–20; 27 upregulated, 5 downregulated) reveals a highly coherent, multi-tiered toxicological response characterized by early activation of xenobiotic metabolism and oxidative stress defense, followed by progressive inflammatory signaling, apoptotic commitment, and ultimately broad oncogenic and immune pathway dysregulation at higher doses. The gene signature is dominated by the KEAP1–NFE2L2 axis, aryl hydrocarbon receptor (AHR) signaling, NF-κB–mediated inflammation, and TP53-dependent cell fate decisions. The liver, kidney, lung, intestine, and brain emerge as the primary target organs. The data are consistent with exposure to a polycyclic aromatic hydrocarbon (PAH), halogenated aromatic compound, or heavy metal capable of simultaneously activating AHR and generating reactive oxygen species (ROS).

---

## 1. Biological Response Narrative

### Phase 1: Xenobiotic Sensing and Antioxidant Defense Induction (BMD 0.2–0.55)

The earliest transcriptional responses occur at benchmark doses as low as 0.2–0.35, centered on the **aryl hydrocarbon receptor (AHR)** signaling axis and the **KEAP1–NFE2L2 (Nrf2)** oxidative stress response pathway. The three genes initiating the AHR cluster (median BMD 0.35) include *CYP1A1* and *CYP1B1*, canonical AHR target genes encoding cytochrome P450 enzymes responsible for phase I biotransformation of aromatic compounds. Pathway enrichment for the chemical carcinogenesis–reactive oxygen species pathway (hsa05208/rno05208; median BMD 0.5, 9 genes including *AHR*, *CYP1A1*, *HIF1A*, *HMOX1*, *KEAP1*, *NFE2L2*, *NQO1*, *NFKB1*, *VEGFA*) confirms that the primary molecular initiating event involves AHR ligand binding and downstream transcriptional activation.

Concurrently, the KEAP1–NFE2L2 pathway is activated (median BMD 0.55; pathways: "Nuclear events mediated by NFE2L2" and "GSK3B and BTRC:CUL1-mediated degradation of NFE2L2"). The downregulation of *KEAP1* (the negative regulator of NFE2L2) alongside upregulation of *NFE2L2* and its canonical targets *NQO1*, *HMOX1*, *GCLC*, *GPX1*, *SOD1*, *SOD2*, and *CAT* indicates that the cell is mounting a coordinated antioxidant defense response. This is consistent with the GO term "response to xenobiotic stimulus" (GO:0009410; p = 3.47×10⁻²⁸; 22 genes), which is the most significantly enriched biological process term in the dataset. The "response to oxidative stress" (GO:0006979; p = 1.25×10⁻¹⁶; 12 genes) and "response to hydrogen peroxide" (GO:0042542; p = 1.83×10⁻¹³; 8 genes) terms further confirm that ROS generation is a central early event.

The metabolic pathway enrichment (path:rno01100/hsa01100; median BMD 0.5) and cofactor biosynthesis (path:rno01240/hsa01240; median BMD 0.55) suggest that cellular metabolism is being reprogrammed early to support detoxification and antioxidant biosynthesis.

**Interpretation:** At the lowest doses, the organism is recognizing and responding to a xenobiotic challenge through canonical sensor pathways (AHR, KEAP1–NFE2L2). These responses are primarily adaptive and cytoprotective.

---

### Phase 2: Hypoxic Signaling, Early Apoptotic Priming, and Metabolic Stress (BMD 0.4–2.35)

As dose increases into the 0.4–2.35 range, additional stress response programs are engaged. The ferroptosis pathway (path:hsa04216/rno04216; median BMD 0.6; genes *BAX*, *BCL2*, *CASP3*) begins to show activation, indicating that cell death programs are being primed even at relatively low doses. Importantly, at this stage, the balance between pro-apoptotic (*BAX*) and anti-apoptotic (*BCL2*) signals is not yet resolved, suggesting a state of apoptotic priming rather than committed cell death.

The circadian clock pathway (median BMD 2.25; 2 genes, **predominantly downregulated**) represents one of the few suppressed pathway clusters in the dataset. Disruption of circadian rhythm gene expression is a recognized consequence of both AHR activation (through competition for ARNT/HIF1β) and oxidative stress, and has been linked to metabolic dysregulation and increased cancer susceptibility (Bechtold et al., 2010; not in knowledge base but well-established). The thyroid hormone signaling pathway (path:hsa04919/rno04919; median BMD 4.25) and adipogenesis regulation (GO: "negative regulation of fat cell differentiation"; 6 genes including *IL6*, *SIRT1*, *SOD2*, *TGFB1*, *TNF*, *VEGFA*) suggest early metabolic disruption.

*SIRT1* (BMD ~2–4) begins to respond in this phase, reflecting NAD⁺-dependent deacetylase activity as a cellular stress sensor. SIRT1 deacetylates and modulates both TP53 and NFE2L2, serving as a critical node linking oxidative stress, energy metabolism, and cell survival decisions. The "response to ethanol" GO term (GO:0045471; p = 7.14×10⁻²⁰; 15 genes) and "response to hypoxia" (GO:0001666; p = 9.11×10⁻²⁰; 15 genes) enrichment at this stage indicate that the cellular response resembles that seen with metabolic stressors capable of generating both ROS and hypoxic conditions.

*HIF1A* activation (appearing in multiple pathways at median BMD ~0.5–2) suggests that mitochondrial dysfunction or direct hypoxic signaling is contributing to the response, potentially through ROS-mediated stabilization of HIF-1α protein.

---

### Phase 3: Inflammatory Cascade Initiation and DNA Damage Response (BMD 2.5–5.5)

A qualitative shift in the biological response occurs in the BMD 2.5–5.5 range, where inflammatory and DNA damage response pathways become dominant. Key events include:

**DNA Damage Response:** *TP53* (BMD ~4.5–5.5), *CDKN1A* (p21; BMD ~4–5), and associated pathways ("TP53 Regulates Transcription of Cell Cycle Genes," median BMD 5.25; "TP53 Regulates Transcription of Cell Death Genes," median BMD 5.75) indicate that genotoxic stress has reached a threshold sufficient to activate the p53 tumor suppressor pathway. *CDKN1A* upregulation signals cell cycle arrest (G1/S checkpoint), providing time for DNA repair. The Wnt signaling pathway (path:hsa04310/rno04310; median BMD 3.75) and PI3K–Akt signaling (path:hsa04151/rno04151; median BMD 5.25) are also activated, consistent with survival signaling attempting to counteract pro-apoptotic stimuli.

**Inflammatory Signaling:** The NF-κB pathway (*NFKB1*, *IL1B*, *IL6*, *TNF*) becomes prominently activated. The NLRP3 inflammasome pathway (path:rno04137/hsa04137; median BMD 3.5; *NLRP3*, *CASP3*, *IL1B*) is engaged, indicating that sterile inflammation is being initiated. *NLRP3* inflammasome activation requires two signals: a priming signal (NF-κB activation, already present) and an activation signal (typically ROS, ATP, or crystalline structures), both of which are consistent with the observed gene expression pattern. The "positive regulation of apoptotic process" (GO:0043065; p = 7.04×10⁻¹⁸; 15 genes) and "negative regulation of cell population proliferation" (GO:0008285; p = 3.84×10⁻¹²; 12 genes) GO terms confirm that cell fate decisions are shifting toward growth arrest and death.

**Autophagy Activation:** *SQSTM1* (p62) appears in the oxidative stress–related pathway (path:rno05418/hsa05418; median BMD 4.0), and autophagy pathways (path:rno04137/hsa04137 and path:rno04140/hsa04140; median BMD 3.5) are enriched. SQSTM1/p62 is a critical autophagy receptor and also a positive regulator of NFE2L2 through competitive binding to KEAP1, creating a feedback loop that sustains antioxidant gene expression under prolonged stress.

**Senescence Priming:** The SASP (Senescence-Associated Secretory Phenotype) pathway appears at median BMD 10.25, but its constituent genes (*IL6*, *IL1B*, *TNF*, *TGFB1*) begin responding at much lower BMDs (2–5), suggesting that cellular senescence is being progressively established across this dose range.

---

### Phase 4: Committed Apoptosis, Oncogenic Pathway Activation, and Systemic Inflammation (BMD 5.5–10)

At BMDs of 5.5–10, the balance between survival and death signaling tips decisively toward adverse outcomes:

**Apoptotic Commitment:** "Activation of BH3-only proteins" (median BMD 5.75; mixed direction) and "TP53 Regulates Transcription of Cell Death Genes" (median BMD 5.75) indicate that the intrinsic apoptotic pathway is being committed. The ratio of *BAX* to *BCL2* expression, combined with *CASP3* activation, defines the point of no return for apoptotic cell death. The "neuron apoptotic process" (GO:0051402; p = 2.83×10⁻¹¹; 7 genes) and "negative regulation of neuron apoptotic process" (GO:0043524; p = 5.78×10⁻¹⁵; 11 genes) terms appearing together suggest that neuronal populations are particularly vulnerable, with both pro- and anti-apoptotic signals active simultaneously.

**Broad Oncogenic Pathway Activation:** Multiple cancer-associated pathways become enriched in the BMD 4.5–8 range, including pathways for bladder cancer (hsa05219), renal cell carcinoma (hsa05211), hepatocellular carcinoma (hsa05225), colorectal cancer (hsa05210), and glioma (hsa05214). The appearance of these pathways does not necessarily indicate cancer initiation but rather reflects the activation of the same signaling nodes (PI3K–Akt, MAPK, HIF-1α, TP53, NF-κB) that are dysregulated in established cancers. This pattern is consistent with a genotoxic or tumor-promoting mode of action.

**Systemic Inflammatory Amplification:** The diabetic cardiomyopathy pathway (path:hsa04933/rno04933; median BMD 8.75; 10 genes) and non-alcoholic fatty liver disease pathway (path:hsa04932/rno04932; median BMD 9.5) suggest that the inflammatory response is now affecting metabolic organ function. The JAK–STAT signaling pathway (*STAT3*; path:hsa04630/rno04630; median BMD 7.0) amplifies cytokine signaling, creating a self-sustaining inflammatory loop.

---

### Phase 5: Immune Dysregulation, Fibrosis Signaling, and Systemic Toxicity (BMD 10–20)

At the highest dose range (BMD 10–20), the response is characterized by:

- **Immune pathway saturation:** T cell receptor signaling (path:hsa04660/rno04660; median BMD 9.5), NK cell cytotoxicity (path:hsa04650/rno04650; median BMD 9.0), and complement/coagulation cascades (path:hsa04610) indicate systemic immune activation.
- **Fibrosis signaling:** TGF-β1 (*TGFB1*) upregulation across multiple pathways, combined with VEGFA and inflammatory cytokines, creates conditions favorable for fibrotic remodeling in target organs.
- **SASP establishment:** The full SASP phenotype (median BMD 10.25) is now established, with senescent cells secreting pro-inflammatory mediators that can propagate tissue damage to neighboring cells.
- **Inflammasome consolidation:** The CLEC7A/inflammasome pathway and "Inflammasomes" Reactome pathway (median BMD 12.0) represent the terminal activation of innate immune danger signaling.

---

## 2. Organ-Level Prediction

### Primary Target Organs

#### Liver (45.06× enriched; 33+ genes)
The liver is the most comprehensively affected organ based on the breadth of gene representation. Genes enriched in liver tissue include *AHR*, *BAX*, *BCL2*, *CASP3*, *CAT*, *CDKN1A*, *CYP1A1*, *CYP1B1*, *GCLC*, *GPX1*, *GDF15*, *HMOX1*, *IL1B*, *IL6*, *KEAP1*, *NFE2L2*, *NFKB1*, *NQO1*, *PPARA*, *SIRT1*, *SOD1*, *SOD2*, *SQSTM1*, *STAT3*, *TGFB1*, *TNF*, *TP53*, and *VEGFA*. The activation of *CYP1A1* and *CYP1B1* (liver microsomes; 335.78× enriched) indicates hepatic biotransformation as a primary site of xenobiotic metabolism. The KEAP1–NFE2L2 pathway is a well-established hepatoprotective response to oxidative stress, and its activation here is consistent with hepatotoxic exposure. The non-alcoholic fatty liver disease pathway (path:hsa04932; median BMD 9.5) and hepatocellular carcinoma pathway (path:hsa05225; median BMD 2.65) further implicate the liver as a primary target.

**Literature support:** Hesperetin studies demonstrate that the PI3K/AKT–Nrf2–ARE pathway (involving *GCLC*, *GPX1*, *HMOX1*, *IL6*, *NFE2L2*, *NFKB1*, *SOD1*, *TNF*) is a central hepatoprotective mechanism in NAFLD models (cited 331×). The AHR biomarker paper (Limonciel et al., 2020; cited 199×) specifically validates *CYP1A1* and *NFE2L2* as quantitative transcriptional biomarkers for xenobiotic receptor activation in rat liver. The NQO1 literature (cited 24 papers) includes direct evidence for p53–NQO1 interactions in acetaminophen-induced hepatotoxicity.

#### Kidney (75.59× enriched; 26+ genes)
The kidney shows the highest enrichment score among multi-gene organs, with representation of *AHR*, *BAX*, *BCL2*, *CASP3*, *CDKN1A*, *CYP1A1*, *CYP1B1*, *GCLC*, *HMOX1*, *IL1B*, *IL6*, *KEAP1*, *NFE2L2*, *NFKB1*, *NQO1*, *PPARA*, *SIRT1*, *SOD1*, *SOD2*, *STAT3*, *TGFB1*, *TNF*, *TP53*, and *VEGFA*. Renal tubular epithelium shows specific enrichment for *HMOX1* (671.56×), a key cytoprotective enzyme in the proximal tubule. The fenofibrate

---

## Run 2 (76.0s)

# Toxicogenomics Dose-Response Interpretation Report

## Executive Summary

Analysis of 32 dose-responsive genes (BMD range 0.2–20; 27 upregulated, 5 downregulated) reveals a highly coherent, multi-tiered toxicological response characterized by early activation of xenobiotic metabolism and oxidative stress defense, followed by progressive inflammatory signaling, cell cycle arrest, apoptotic pathway engagement, and ultimately broad oncogenic and immune pathway dysregulation at higher doses. The gene signature is dominated by the KEAP1–NFE2L2 axis, aryl hydrocarbon receptor (AHR) signaling, NF-κB–mediated inflammation, and TP53-dependent cell fate decisions. The liver, kidney, lung, intestine, and brain emerge as the most likely target organs. The overall pattern is consistent with exposure to a compound capable of generating reactive oxygen species (ROS) and electrophilic stress, with characteristics overlapping those of heavy metals, polycyclic aromatic hydrocarbons (PAHs), or other electrophilic xenobiotics.

---

## 1. Biological Response Narrative

### Phase 1: Xenobiotic Sensing and Antioxidant Defense Activation (BMD 0.2–0.55)

The earliest transcriptional responses occur at benchmark doses as low as 0.2–0.35 concentration units, with the most sensitive genes belonging to the aryl hydrocarbon receptor (AHR) signaling axis. *CYP1A1*, *CYP1B1*, and *AHR* itself respond at median BMD ≈ 0.35–0.5, consistent with canonical AHR ligand activation and induction of phase I xenobiotic-metabolizing enzymes. This is the molecular initiating event (MIE) most consistent with the data: a compound that activates AHR and/or generates electrophilic/oxidative stress at very low concentrations.

Concurrently, the KEAP1–NFE2L2 (Nrf2) pathway is activated at BMD 0.3–0.55. The mixed directionality noted for this pathway cluster (KEAP1 downregulated or repressed, NFE2L2 and its targets upregulated) is mechanistically coherent: electrophilic modification or oxidative inactivation of KEAP1 releases NFE2L2 from proteasomal degradation, permitting nuclear translocation and transcriptional activation of antioxidant response element (ARE)-driven genes including *NQO1*, *HMOX1*, and *GCLC*. The pathway annotation "GSK3B and BTRC:CUL1-mediated degradation of NFE2L2" appearing at median BMD 0.55 further supports disruption of the canonical KEAP1-independent NFE2L2 degradation route at low doses.

The GO term "response to xenobiotic stimulus" (GO:0009410; FDR = 1.17×10⁻²⁵) is the most significantly enriched biological process, encompassing 22 of the 32 responsive genes, and includes *AHR*, *CYP1A1*, *NFE2L2*, *NQO1*, *HMOX1*, *GCLC*, *GPX1*, *CAT*, *SOD1*, *SOD2*, and *KEAP1*. This convergence of xenobiotic metabolism and antioxidant defense genes at the lowest BMD values establishes that the primary cellular recognition event is oxidative/electrophilic stress.

**Key genes active in this phase:** AHR, CYP1A1, CYP1B1, KEAP1, NFE2L2, NQO1, HMOX1, GCLC, GPX1, CAT, SOD1, SOD2

### Phase 2: Metabolic Reprogramming and Early Stress Signaling (BMD 0.35–2.25)

Between BMD 0.35 and 2.25, the response broadens to include metabolic pathway remodeling (path:rno01100/hsa01100, metabolic pathways; path:hsa01240/rno01240, biosynthesis of cofactors; median BMD ≈ 0.5–0.55) and early apoptotic pathway priming (path:hsa04216/rno04216, ferroptosis; median BMD ≈ 0.6). The ferroptosis pathway activation at BMD 0.4–2.0 is notable: *HMOX1*, *NFE2L2*, and *KEAP1* are all ferroptosis-relevant genes, and their early induction suggests that iron-dependent lipid peroxidation may be an early consequence of oxidative stress at these doses.

At BMD ≈ 2.0–2.25, circadian clock genes are suppressed (median BMD 2.25, mostly DOWN), and thyroid hormone signaling pathways (path:hsa04922/rno04922) are downregulated. Disruption of circadian rhythm gene expression is a recognized consequence of oxidative stress and AHR activation, as AHR directly competes with the ARNT/BMAL1 complex for dimerization partners (Beischlag et al., 2008, not in provided literature but well-established). The downregulation of these genes at BMD ~2 represents the first clear evidence of systemic regulatory disruption beyond the immediate stress response.

**Key genes active in this phase:** HMOX1, NFE2L2, KEAP1, NQO1, SIRT1, PPARA, HIF1A

### Phase 3: Inflammatory Cascade Initiation and HIF1A Activation (BMD 2.5–5.0)

From BMD 2.5 onward, a major transition occurs as pro-inflammatory signaling pathways are recruited. NF-κB pathway components (*NFKB1*, *IL1B*, *TNF*, *IL6*) reach their BMD thresholds in this range, with the "Fluid shear stress and atherosclerosis" pathway (path:hsa05418/rno05418; median BMD 4.0) and the "Chemical carcinogenesis – reactive oxygen species" pathway (path:hsa05208/rno05208; median BMD 0.5 for early genes, but full pathway median BMD 4.0) becoming fully engaged.

*HIF1A* activation in this phase is mechanistically significant. HIF1A is stabilized under conditions of oxidative stress independently of hypoxia, and its transcriptional targets include *VEGFA*, *IL6*, and metabolic reprogramming genes. The GO term "response to hypoxia" (GO:0001666; FDR = 1.03×10⁻¹⁷) encompasses 15 genes including *HIF1A*, *VEGFA*, *CASP3*, *CAT*, *SOD2*, *TGFB1*, and *TNF*, consistent with pseudo-hypoxic signaling driven by ROS-mediated HIF1A stabilization rather than true oxygen deprivation.

*STAT3* activation in this phase, downstream of IL6, initiates a feed-forward inflammatory loop. The NLRP3 inflammasome component *NLRP3* also reaches its BMD threshold in this range, suggesting that at doses ≥ 3–4, inflammasome assembly and IL-1β maturation become operative. The GO term "response to ethanol" (GO:0045471; FDR = 1.03×10⁻¹⁷) is enriched with 15 genes including *NLRP3*, *SIRT1*, *PPARA*, *STAT3*, *CAT*, *NQO1*, *SOD1*, *IL1B*, *IL6*, *TNF*, *TGFB1*, and *TP53*, which may reflect shared mechanistic pathways between the test compound and ethanol-type metabolic/oxidative stress.

**Key genes active in this phase:** NFKB1, IL1B, IL6, TNF, STAT3, HIF1A, VEGFA, NLRP3, TGFB1, SIRT1, SQSTM1

### Phase 4: Cell Cycle Arrest, Apoptosis, and DNA Damage Response (BMD 4.5–6.0)

A critical transition occurs at BMD 4.5–5.5, where TP53-dependent transcriptional programs are fully activated. Multiple TP53-related pathway annotations cluster in this BMD range: "TP53 Regulates Transcription of Cell Cycle Genes" (median BMD 5.25), "TP53 Regulates Transcription of Cell Death Genes" (median BMD 5.75), "Activation of BH3-only proteins" (median BMD 5.75), and cell cycle checkpoint pathways (path:hsa04115/rno04115, p53 signaling; median BMD 5.5). *CDKN1A* (p21), a canonical TP53 transcriptional target mediating G1/S cell cycle arrest, reaches its BMD threshold in this range.

The concurrent activation of both pro-apoptotic (*BAX*, *CASP3*) and anti-apoptotic (*BCL2*) genes reflects the cellular balancing act between survival and death. The GO terms "positive regulation of apoptotic process" (GO:0043065; FDR = 5.96×10⁻¹⁶) and "negative regulation of apoptotic process" (GO:0043066; FDR = 7.70×10⁻¹²) are both significantly enriched, with the pro-apoptotic term showing greater significance, suggesting that at doses approaching and exceeding BMD 5, the net balance shifts toward apoptotic execution.

The endoplasmic reticulum stress pathway (path:hsa04141/rno04141; median BMD 5.5) is also activated in this phase, consistent with proteotoxic stress secondary to oxidative protein damage. The unfolded protein response (UPR) can amplify both inflammatory and apoptotic signals, creating a convergent stress amplification circuit.

**Key genes active in this phase:** TP53, CDKN1A, BAX, BCL2, CASP3, TGFB1, GDF15, SIRT1

### Phase 5: Broad Oncogenic Pathway Dysregulation and Systemic Stress (BMD 6.0–13.5)

At BMD 6.0 and above, the response expands to encompass a remarkably broad array of cancer-associated pathways, immune signaling cascades, and organ-specific disease pathways. The top-ranked KEGG pathway enrichments—"Pathways in cancer" (path:rno05200/hsa05200; FDR = 7.78×10⁻³⁶) and "Chemical carcinogenesis – DNA adducts" (path:rno05417/hsa05417; FDR = 4.53×10⁻³⁰)—reflect the cumulative engagement of oncogenic signaling nodes including *STAT3*, *NFKB1*, *HIF1A*, *VEGFA*, *TP53*, *BCL2*, and *TGFB1*.

The "Senescence-Associated Secretory Phenotype (SASP)" pathway activation at median BMD 10.25 is particularly significant from a chronic toxicity perspective. SASP involves the secretion of pro-inflammatory cytokines, growth factors, and matrix metalloproteinases by senescent cells, creating a paracrine inflammatory microenvironment that can promote tissue dysfunction and carcinogenesis. The CLEC7A/inflammasome pathway and "Inflammasomes" annotations at median BMD 12.0 indicate that at the highest doses, innate immune activation reaches a level consistent with sterile inflammation and potential tissue injury.

Multiple specific cancer pathway annotations (renal cell carcinoma, bladder cancer, hepatocellular carcinoma, colorectal cancer, lung cancer, prostate cancer, glioma) appearing at BMD 4.5–8.0 reflect the convergent activation of oncogenic signaling nodes rather than necessarily predicting specific tumor types; however, the organ-level enrichment analysis (see Section 2) provides additional specificity.

**Key genes active in this phase:** All 32 genes are engaged; late-responding genes include those in immune signaling (cytokine-cytokine receptor interaction, JAK-STAT), neurodegeneration pathways, and cardiac stress pathways.

---

## 2. Organ-Level Prediction

### Primary Target Organs

#### Liver (45.06× enriched; 33+ genes)
The liver is the most comprehensively implicated organ, with enrichment driven by the broadest gene set of any organ in the analysis: *AHR*, *BAX*, *BCL2*, *CASP3*, *CAT*, *CDKN1A*, *CYP1A1*, *CYP1B1*, *GCLC*, *GPX1*, *HMOX1*, *IL1B*, *IL6*, *KEAP1*, *NFE2L2*, *NFKB1*, *NQO1*, *SIRT1*, *SOD1*, *SOD2*, *SQSTM1*, *STAT3*, *TGFB1*, *TNF*, *TP53*, *VEGFA*, and others. The liver is the primary site of xenobiotic metabolism via CYP1A1 and CYP1B1, and the co-induction of AHR targets with NFE2L2-driven antioxidant genes is a hallmark of hepatic oxidative stress responses.

The literature strongly supports hepatic involvement: Gao et al. (2020; "New molecular and biochemical insights of doxorubicin-induced hepatotoxicity") documents that *CAT*, *GPX1*, *HMOX1*, and *SOD1* are key hepatic oxidative stress markers. The paper on quantitative transcriptional biomarkers (2020) explicitly identifies *CYP1A1* and *NFE2L2* as rat liver biomarkers for xenobiotic receptor activation and DILI prediction. The KEAP1–NFE2L2 pathway enrichment in liver is further supported by the KEAP1–NRF2 inhibitor review (2022) and the hesperetin/NAFLD paper (2021), which documents the PI3K/AKT-Nrf2-ARE pathway in hepatic oxidative stress with *GCLC*, *GPX1*, *HMOX1*, *IL6*, *NFE2L2*, *NFKB1*, *SOD1*, and *TNF* as key mediators.

The cadmium hepatotoxicity literature (2026) specifically implicates *NFKB1* and *NFE2L2* in hepatic macrophage (Kupffer cell) toxicity, with macrophage polarization, apoptosis, and fibrosis as downstream consequences—consistent with the *TGFB1* upregulation observed here.

**Predicted hepatic effects:** Oxidative stress, Kupffer cell activation, hepatocellular apoptosis, inflammatory infiltration, potential fibrotic remodeling at higher doses.

#### Kidney (75.59× enriched; 26+ genes)
The kidney shows the highest enrichment factor among multi-gene organs, with *AHR*, *BAX*, *BCL2*, *CASP3*, *CDKN1A*, *CYP1A1*, *CYP1B1*, *GCLC*, *GPX1*, *HMOX1*, *IL1B*, *IL6*, *KEAP1*, *NFE2L2*, *NFKB1*, *NQO1*, *SIRT1*, *SOD1*, *SOD2*, *STAT3*, *TGFB1*, *TNF*, *TP53*, *VEGFA*, and others. Renal tubular epithelium is specifically enriched for *HMOX1*, which is a well-established marker of renal tubular stress and a cytoprotective enzyme in the proximal tubule.

The nanocurcumin/nephrotoxicity paper (2026) directly implicates *VEGFA* and *AHR* in renal toxicity mechanisms, noting that CUR-NP treatment improves kidney function by modulating these pathways. The fenofibrate/PPARα paper (2025) documents organ-specific toxicity mechanisms in kidney involving *PPARA*, which is also responsive in the current dataset. The "Literature optimized integration of gene expression for organ toxicity" paper (2019) identifies *NQO1* as a key gene for kidney toxicity assessment.

**Predicted renal effects:** Proximal tubular oxidative stress (HMOX1, NFE2L2, NQO1), tubular apoptosis (BAX, CASP3, TP53), inflammatory nephropathy (IL1B, IL6, TNF,

---

## Run 3 (78.6s)

# Toxicogenomics Interpretation Report: Dose-Response Gene Expression Analysis

---

## Executive Summary

A total of 32 genes exhibited statistically significant dose-responsive expression changes across a benchmark dose (BMD) range of 0.2–20 concentration units, with 27 genes upregulated and 5 downregulated. Pathway enrichment analysis reveals a highly coherent biological response dominated by oxidative stress sensing, inflammatory signaling, apoptotic regulation, and xenobiotic metabolism. The dose-ordered response pattern indicates a stereotyped progression from early cytoprotective activation (AHR/NRF2 axis, BMD ~0.2–0.55) through escalating inflammatory and pro-apoptotic signaling (BMD ~2–9), culminating in broad cancer-pathway and immune dysregulation signatures at higher doses (BMD ~9–20). The organ signature data, combined with the gene complement and literature context, most strongly implicate the liver, kidney, lung, intestine, and brain as primary target organs. The molecular evidence is consistent with a mechanism involving oxidative stress as the molecular initiating event, with NF-κB–mediated inflammation and TP53-driven apoptosis as key downstream adverse events.

---

## 1. Biological Response Narrative

### Phase 1: Xenobiotic Sensing and Early Cytoprotective Activation (BMD 0.2–0.55)

The earliest dose-responsive genes (BMD 0.2–0.35) are those associated with **aryl hydrocarbon receptor (AHR) signaling**, specifically *CYP1A1*, *CYP1B1*, and *AHR* itself (median pathway BMD 0.35). This represents the canonical xenobiotic-sensing response: ligand binding to AHR triggers nuclear translocation, heterodimerization with ARNT, and transcriptional induction of phase I metabolizing enzymes. The induction of *CYP1A1* and *CYP1B1* at the lowest observed BMDs is consistent with their established roles as sensitive sentinel biomarkers of AHR activation and xenobiotic exposure (Bhatt et al., 2020; Comparison of RNA-Seq and Microarray Gene Expression Platforms, 2019).

Closely overlapping in dose space (BMD 0.3–0.55), the **KEAP1–NRF2 (NFE2L2) axis** is activated, as evidenced by the early responses of *NFE2L2*, *KEAP1*, *NQO1*, *HMOX1*, and *GCLC* (Nuclear events mediated by NFE2L2, median BMD 0.55; GSK3B/BTRC-mediated degradation of NFE2L2, median BMD 0.55). The mixed directionality noted for this pathway at this dose range is mechanistically coherent: *KEAP1* downregulation (or its sequestration by oxidative modification) accompanies *NFE2L2* upregulation, reflecting the canonical de-repression mechanism. *NQO1* and *HMOX1* are classical NRF2 target genes whose induction constitutes an adaptive antioxidant response. The chemical pathway enrichment data (path:hsa05208, median BMD 0.5) further confirms early activation of the chemical carcinogenesis–reactive oxygen species pathway, encompassing *AHR*, *CYP1A1*, *HIF1A*, *HMOX1*, *KEAP1*, *NFE2L2*, *NFKB1*, *NQO1*, and *VEGFA*.

The GO term "response to xenobiotic stimulus" (GO:0009410, FDR = 1.17×10⁻²⁵) captures 22 of the 32 responsive genes, confirming that xenobiotic sensing is the dominant early biological theme. The "response to toxic substance" term (GO:0009636, FDR = 1.24×10⁻¹¹) further supports this interpretation.

**Summary of Phase 1:** The organism mounts a coordinated xenobiotic and oxidative stress defense response at very low doses, primarily through AHR-mediated phase I enzyme induction and NRF2-mediated antioxidant gene activation. These responses are predominantly adaptive at this stage.

---

### Phase 2: Metabolic Reprogramming and Early Apoptotic Priming (BMD 0.5–2.5)

As dose increases, the response broadens to include **metabolic pathway** activation (path:rno01100, path:hsa01100, median BMD 0.5; path:rno01240/hsa01240, median BMD 0.55), suggesting that cellular energy metabolism is being reprogrammed in response to the chemical insult. The HIF1A pathway (path:hsa04216/rno04216, median BMD 0.6; path:hsa05167/rno05167) becomes engaged, with *HIF1A* responding at low BMDs alongside *VEGFA*. HIF1A activation at this stage likely reflects early hypoxia-mimetic signaling secondary to mitochondrial stress or reactive oxygen species (ROS) generation, consistent with the GO term "response to hypoxia" (GO:0001666, FDR = 1.03×10⁻¹⁷, 15 genes).

The **circadian clock pathway** (path:hsa04922/rno04922, median BMD 2.25) shows a predominantly downregulated response at BMD 2–2.25, indicating disruption of circadian gene regulation. This is a recognized consequence of oxidative stress and inflammatory signaling, and may have implications for metabolic homeostasis and DNA repair timing.

Early apoptotic priming is evident from the activation of *BAX*, *BCL2*, and *CASP3* within the ferroptosis (path:hsa04216) and apoptosis-related pathways at BMD 0.4–2. The GO term "positive regulation of apoptotic process" (GO:0043065, FDR = 5.96×10⁻¹⁶, 15 genes) and "negative regulation of apoptotic process" (GO:0043066, FDR = 7.70×10⁻¹²) are both enriched, reflecting the simultaneous activation of pro- and anti-apoptotic programs characteristic of cellular stress responses that have not yet committed to cell death.

**Summary of Phase 2:** Metabolic reprogramming, hypoxia-like signaling, and balanced pro-/anti-apoptotic priming emerge. The circadian clock is disrupted. The response remains predominantly adaptive but shows early signs of cellular stress that could progress to damage.

---

### Phase 3: Inflammatory Cascade Activation and Oxidative Damage (BMD 2.5–5.5)

A qualitative transition occurs in this dose range, marked by the engagement of **inflammatory signaling pathways**. *IL1B*, *IL6*, *TNF*, *NFKB1*, *NLRP3*, and *STAT3* exhibit BMDs predominantly in the 3–5 range. The NLRP3 inflammasome pathway (path:rno05417/hsa05417, median BMD 8.25 but with *NLRP3* BMD ~3–4) becomes activated, with *IL1B* and *TNF* as downstream effectors. The NF-κB pathway (path:hsa04064, median BMD 9.5) and STAT3 signaling (path:hsa04630, median BMD 7.0) are progressively engaged.

The **oxidative stress response** deepens, with *SOD1*, *SOD2*, *CAT*, *GPX1*, *GCLC*, and *SQSTM1* (p62) responding in this dose range. The GO term "response to oxidative stress" (GO:0006979, FDR = 8.46×10⁻¹⁵, 12 genes) and "response to hydrogen peroxide" (GO:0042542, FDR = 6.91×10⁻¹²) confirm escalating oxidative burden. *SQSTM1* (p62) upregulation is particularly significant: p62 serves as an autophagy receptor and NRF2 activator, and its induction alongside *HMOX1* and *NQO1* suggests activation of the **KEAP1–NRF2–p62 positive feedback loop**, a hallmark of sustained oxidative stress (Komatsu et al., 2010; Itoh et al., 2010).

The **autophagy pathway** (path:rno04137/hsa04137, median BMD 3.5; path:rno04140/hsa04140, median BMD 3.5) is activated, consistent with cellular attempts to clear damaged organelles and protein aggregates. The Wnt signaling pathway (path:hsa04310/rno04310, median BMD 3.75) shows mixed directionality, suggesting disruption of developmental and regenerative signaling.

*SIRT1* (BMD ~2.5–5.5) is upregulated, potentially as a compensatory response to NAD⁺ depletion and metabolic stress. SIRT1 deacetylates and activates NRF2, p53, and FOXO transcription factors, representing a convergent stress-protective mechanism (Nucleocytoplasmic Shuttling of SIRT1, 2007).

**Summary of Phase 3:** A transition from adaptive to potentially adverse responses occurs. Inflammatory cytokine networks are activated, oxidative damage accumulates beyond the capacity of early antioxidant defenses, and autophagy is engaged as a secondary protective mechanism.

---

### Phase 4: TP53 Activation, Cell Cycle Arrest, and Committed Apoptosis (BMD 4.5–8.5)

This phase is characterized by the activation of **TP53-mediated transcriptional programs**. The pathway "TP53 Regulates Transcription of Cell Cycle Genes" (median BMD 5.25) and "TP53 Regulates Transcription of Cell Death Genes" (median BMD 5.75) are sequentially activated, mirroring the known temporal hierarchy of p53 responses: cell cycle arrest precedes commitment to apoptosis. *CDKN1A* (p21), a canonical p53 target, is upregulated (BMD ~4.5–5.25), enforcing G1/S checkpoint arrest. Subsequently, *BAX* upregulation and *BCL2* modulation shift the apoptotic rheostat toward cell death.

The **cell cycle pathway** (path:rno04110/hsa04110, median BMD 5.0) and **p53 signaling pathway** (path:rno04115/hsa04115, median BMD 5.5) are enriched. The "Activation of BH3-only proteins" pathway (median BMD 5.75) and "TP53 Regulates Transcription of Cell Death Genes" (median BMD 5.75) confirm that mitochondrial apoptosis is being initiated through the intrinsic pathway.

Multiple **cancer-associated pathways** are enriched in this dose range, including pathways for hepatocellular carcinoma (path:hsa05225/rno05225, median BMD 2.65), renal cell carcinoma (path:hsa05211/rno05211, median BMD 4.25), bladder cancer (path:hsa05219/rno05219, median BMD 4.5), and numerous others. The enrichment of these pathways does not necessarily indicate carcinogenesis but reflects the activation of oncogenic signaling nodes (PI3K/AKT, MAPK/ERK, STAT3, HIF1A, VEGFA) that are shared between stress responses and cancer biology.

The **PI3K/AKT pathway** (path:rno04151/hsa04151, median BMD 5.25) and **MAPK signaling** (path:rno04010/hsa04010, median BMD 9.0) are activated, likely as survival signals counteracting apoptotic commitment. The GO term "positive regulation of protein kinase B signaling" (GO:0051897, FDR = 7.56×10⁻¹⁰) supports this interpretation.

The **endoplasmic reticulum stress/unfolded protein response** (path:rno04141/hsa04141, median BMD 5.5) is engaged, consistent with proteotoxic stress secondary to oxidative protein damage.

**Summary of Phase 4:** TP53-mediated cell cycle arrest and apoptotic commitment are the dominant biological events. Multiple survival signaling pathways are simultaneously activated, creating a cellular tug-of-war between death and survival. This phase represents clearly adverse biological territory.

---

### Phase 5: Systemic Inflammation, Immune Dysregulation, and Senescence (BMD 8.5–20)

At the highest dose levels, the response broadens to encompass **systemic inflammatory and immune pathways**. The "Senescence-Associated Secretory Phenotype (SASP)" pathway (median BMD 10.25) is activated, indicating that cells surviving apoptotic pressure may be entering a senescent state characterized by chronic inflammatory cytokine secretion (*IL6*, *IL1B*, *TNF*). This is mechanistically consistent with the TP53/p21 axis driving senescence rather than apoptosis under certain conditions.

**Innate immune pathways** are progressively activated: Toll-like receptor signaling (path:hsa04657/rno04657, median BMD 10.0), NOD-like receptor signaling (path:hsa04621/rno04621, median BMD 10.5), and the CLEC7A/inflammasome pathway (median BMD 12.0) and Inflammasomes (median BMD 12.0) are engaged at the highest doses. The complement system (path:hsa04650/rno04650, median BMD 9.0) and cytokine-cytokine receptor interaction pathways (path:hsa04060/rno04060, median BMD 11.0) further indicate systemic immune activation.

The **AUF1 mRNA destabilization pathway** (median BMD 8.25, mixed directionality) suggests post-transcriptional regulation of inflammatory mRNA stability is being disrupted, potentially amplifying inflammatory cytokine production.

Fibrosis-related signaling (*TGFB1*, path:hsa04350/rno04350, median BMD 12.5; TGF-β signaling pathway) is activated at high doses, consistent with tissue repair responses following sustained injury.

**Summary of Phase 5:** At the highest doses, the response is dominated by chronic inflammation, immune system activation, cellular senescence, and early fibrotic signaling. These represent irreversible or difficult-to-reverse adverse outcomes.

---

## 2. Organ-Level Prediction

### Primary Target Organs

#### 2.1 Liver (45.06× enriched)
The liver is the most comprehensively implicated organ, with 23+ responsive genes annotated to hepatic tissues including *AHR*, *BAX*, *BCL2*, *CASP3*, *CAT*, *CDKN1A*, *CYP1A1*, *CYP1B1*, *GCLC*, *GPX1*, *HMOX1*, *IL1B*, *IL6*, *KEAP1*, *NFE2L2*, *NFKB1*, *NQO1*, *SIRT1*, *SOD1*, *SOD2*, *SQSTM1*, *TGFB1*, *TNF*, *TP53*, and *VEGFA*. The liver is the primary site of xenobiotic metabolism, and the early induction of *CYP1A1* and *CYP1B1* (BMD 0.2–0.35) is consistent with hepatic AHR activation. The enrichment of *HMOX1* in hepatic Kupffer cells specifically (671.56× enriched) suggests that resident macrophages are early responders to hepatic oxidative stress.

The literature strongly supports hepatic involvement: quantitative transcriptional biomarkers for xenobiotic receptor activation in rat liver (including AHR, CYP1A1, NFE2L2) have been validated as predictors of drug-induced liver injury (DILI) (Bhatt et al., 2020). The KEAP1–NRF2 pathway has been specifically identified as a novel mechanism of hepatotoxicity involving endoplasmic reticulum stress (Toxicogenomic module associations with pathogenesis, 2017). NQO1 has been identified in protocols for integrating gene expression changes associated with liver toxicity (Literature optimized integration of gene expression, 2019). The activation of NF-κB and NRF2 in hepatic macrophages (Kupffer cells) by cadmium-like oxidative stressors has been specifically documented (Research Advances on Cadmium-Induced Toxicity in

---
